Page 6 - Angle Plc News Today

Investegate announcements from Angle PLC, Issue of Equity

Investegate announcements from Angle PLC, Issue of Equity

Investegate announcements from Angle PLC, Study shows use of Parsortix to assess PD-L1

Investegate announcements from Angle PLC, Update on submission for FDA clearance

The group is seeking approval for its Parsortix system to be used with metastatic breast cancer patients in the US

Angle hails Washington University research showing utility of Parsortix system

Scientists successfully used the Parsortix system to harvest disseminated tumour cells, or DTCs, "hibernating" in the bone marrow

ANGLE develops products for use in rare cell diagnostics that enable early, accurate identification of an individual’s condition for the prevention,...

ANGLE reports encouraging results from Parsortix oesophageal cancer study Oesophageal cancer is a deadly disease with 80% patient mortality at 5 years from diagnosis, partly due to late diagnosis ANGLE PLC (LON:AGL) said that a study at the University Hospital Ghent, Belgium showed its liquid biopsy system Parsortix consistently harvested oesophageal cancer cells in patients suffering from the disease. These are the first published results in this cancer type, said ANGLE, and means the Parsort...

About ANGLE plc www.angleplc.com ANGLE is a world leading liquid biopsy company with sample-to-answer solutions. ANGLEs proven patent protected platforms include a circulating tumor cell (CTC) harvesting technology and a downstream analysis system for cost effective, highly multiplexed analysis of nucleic acids and proteins.   ANGLEs cell separation technology is called the Parsortix ®   system, and it enables a liquid biopsy (a simp...